A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEPSponsored Organ Dysfunction Working Group
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2013
At a glance
- Drugs Bortezomib (Primary)
- Indications Liver cancer; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 12 Jun 2013 Planned end date changed from 1 Dec 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 08 Aug 2011 Planned end date changed from 1 Jun 2006 to 1 Dec 2011 as reported by ClinicalTrials.gov .
- 22 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.